NCT06367517View on ClinicalTrials.gov

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2026

Conditions
Orbitopathy, GravesThyroid Eye DiseaseOphthalmopathy
Interventions
DRUG

Tocilizumab

Tocilizumab administrated at a dose of 8 mg/kg, given once every four weeks

Trial Locations (1)

02-097

RECRUITING

Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw

All Listed Sponsors
lead

Medical University of Warsaw

OTHER